Group 1 - The core point of the article is that HeartLink Medical-B (02160.HK) has received CE mark approval for its Alwide Plus cardiac balloon dilation catheter, indicating compliance with health, safety, and environmental standards in the European Economic Area [1] - As of August 18, 2025, HeartLink Medical-B's stock closed at HKD 1.62, reflecting a 9.46% increase with a trading volume of 26.61 million shares and a turnover of HKD 41.78 million [1] - The stock has low attention from investment banks, with no ratings given in the past 90 days [1] Group 2 - HeartLink Medical-B has a market capitalization of HKD 3.571 billion, ranking 12th in the medical device II industry [1] - Key financial metrics for HeartLink Medical-B compared to the medical device I industry average are as follows: - ROE: -2.16% vs. -8.48% (20th rank) - Market capitalization: HKD 3.571 billion vs. HKD 5.866 billion (12th rank) - Revenue: HKD 362 million vs. HKD 1.236 billion (19th rank) - Net profit margin: -14.73% vs. -18.01% (20th rank) - Gross profit margin: 69.48% vs. 55.19% (65th rank) - Debt ratio: 16.97% vs. 27.72% (10th rank) [1]
心通医疗-B(02160.HK)：Alwide Plus心脏瓣膜球囊扩张导管获得CE标志批准